{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T08:11:22Z","timestamp":1794989482991,"version":"4.9.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":126,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.vaccine.2021.05.063","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T12:46:36Z","timestamp":1621860396000},"page":"4423-4428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":925,"title":["Evidence for antibody as a protective correlate for COVID-19 vaccines"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2956-8025","authenticated-orcid":false,"given":"Kristen A.","family":"Earle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Ambrosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Fiore-Gartland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Siber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley A.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.05.063_b0005","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","article-title":"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment","volume":"397","author":"Wouters","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2021.05.063_b0010","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"CVI"},{"key":"10.1016\/j.vaccine.2021.05.063_b0015","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.05.063_b0020","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2034545","article-title":"Antibody status and incidence of SARS-CoV-2 infection in health care workers","volume":"384","author":"Lumley","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.05.063_b0025","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/sim.7996","article-title":"Optimizing and evaluating biomarker combinations as trial-level general surrogates","volume":"38","author":"Gabriel","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2021.05.063_b0030","unstructured":"Novavax. Announcement of UK and South Africa Trial Results. 2021; published online Jan 28. https:\/\/ir.novavax.com\/events\/event-details\/novavax-update-conference-call-and-webcast-0 (accessed March 8, 2021)."},{"key":"10.1016\/j.vaccine.2021.05.063_b0035","unstructured":"Janssen Biotech, Inc. FDA Briefing Document. Janssen Ad26.COV2.S Covid-19 Vaccine for the Prevention of COVID-19. Sponsor Briefing Document Addendum. 2021; published online Feb 26. https:\/\/www.fda.gov\/media\/146218\/download (accessed Feb 26, 2021)."},{"key":"10.1016\/j.vaccine.2021.05.063_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-020-00301-9","article-title":"Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19","volume":"5","author":"Chen","year":"2020","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.vaccine.2021.05.063_b0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4049\/jimmunol.2000898","article-title":"SARS-CoV-2 antibody responses are correlated to disease severity in COVID-19 convalescent individuals","volume":"206","author":"Hansen","year":"2021","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.05.063_b0050","article-title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","author":"Zhou","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2021.05.063_b0055","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.05.063_b0060","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 \u2014 preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.05.063_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2021.03.009","article-title":"The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein","volume":"559","author":"Chen","year":"2021","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2021.05.063_b0070","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant","author":"Madhi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2021.05.063_b0075","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1016\/j.vaccine.2007.01.119","article-title":"Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies","volume":"25","author":"Siber","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.05.063_b0080","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1086\/522428","article-title":"A framework for assessing immunological correlates of protection in vaccine trials","volume":"196","author":"Qin","year":"2007","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21006587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21006587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:57:31Z","timestamp":1759402651000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21006587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":16,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0264410X21006587"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.063","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.03.17.20200246","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence for antibody as a protective correlate for COVID-19 vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}